Stem Cell Processing (Stem Cells in Clinical Applications)

68 Wang L, Li J, Liu H, Li Y, Fu J, Sun Y, Xu R, Lin H, Wang S, Lv S et al (2013b) Pilot study of umbilical cord-derived mesench ...

69 Zhao K, Lou R, Huang F, Peng Y, Jiang Z, Huang K, Wu X, Zhang Y, Fan Z, Zhou H et al (2015a) Immunomodulation effects of mese ...

© Springer International Publishing Switzerland 2016 71 P.V. Pham (ed.), Stem Cell Processing, Stem Cells in Clinical Applicatio ...

72 groups were also statistically indifferent. In another similar study, by Dexheimer and colleagues (Dexheimer et al. 2011 ), M ...

73 3.2 Senescence One important consideration in terms of defi ning ageing is whether it is the indi- vidual cells which have be ...

74 3.3 Tactics to Overcome Ageing The advanced knowledge of how stem cells from aged donors will behave sets the scene for how t ...

75 Fuchs E, Raghavan S (2002) Getting under the skin of epidermal morphogenesis. Nat Rev Genet 3:199–209 Hayfl ick L, Moorhead P ...

© Springer International Publishing Switzerland 2016 77 P.V. Pham (ed.), Stem Cell Processing, Stem Cells in Clinical Applicatio ...

78 (Takahashi and Yamanaka 2006 ). However, compared with ESCs, these iPSCs expressed lower levels of several pluripotent genes ...

79 Several viral vector strategies were used to obtain iPSCs, including retrovirus, lentivirus, adenovirus, and Sendai virus app ...

80 increasing reprogramming effi ciency. One can apply fewer genetic manipulations to preprogram neural progenitor cells in comp ...

81 increased the expression of endogenous DNMT3β, Nanog, Oct4, Rex1, and Sall4. The cells were cultured in human ESC medium, and ...

82 RNA, these strands are easily removed from infected cells using siRNA (Nishimura et al. 2011 ). Viral-free vectors were also ...

83 cell feeder layers (Totonchi et al. 2010 ; Xu et al. 2001 ). iPSCs show excellent growth in Matrigel. However, Matrigel is pr ...

84 4.2.2 Transferring the Manufacturing Process to the GMP Suite To produce iPSCs for clinical application, the procedures from ...

85 megakaryocytes, the mpl knockout mice did not present conventional CAMT human disease (Hirata et al. 2013 ). This fi nding an ...

86 iPSCs, such as hepatic cells, neuron cells, and myocardial cells, could be effectively used for drug screening because of rec ...

87 Another study on drug screening used iPSCs to assess and control the activity of new drugs to treat some diseases, such as ne ...

88 4.3.2.1 iPSCs and Neural Regenerative Medicine Among specifi c cell lineages, neural cells have been considered as the fi rst ...

89 speed of neural induction. However, regardless of the specifi c neural induction strategy used, the main challenge during the ...